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A B S T R A C T
Arterial medial calciﬁcation (AMC) is the deposition of calcium phosphate mineral, often as hydroxyapatite, in
the medial layer of the arteries. AMC shares some similarities to skeletal mineralisation and has been associated
with the transdiﬀerentiation of vascular smooth muscle cells (VSMCs) towards an osteoblast-like phenotype. This
study used primary mouse VSMCs and calvarial osteoblasts to directly compare the established and widely used
in vitro models of AMC and bone formation. Signiﬁcant diﬀerences were identiﬁed between osteoblasts and
calcifying VSMCs. First, osteoblasts formed large mineralised bone nodules that were associated with widespread
deposition of an extracellular collagenous matrix. In contrast, VSMCs formed small discrete regions of calciﬁ-
cation that were not associated with collagen deposition and did not resemble bone. Second, calcifying VSMCs
displayed a progressive reduction in cell viability over time (≤7-fold), with a 50% increase in apoptosis,
whereas osteoblast and control VSMCs viability remained unchanged. Third, osteoblasts expressed high levels of
alkaline phosphatase (TNAP) activity and TNAP inhibition reduced bone formation by to 90%. TNAP activity in
calcifying VSMCs was ∼100-fold lower than that of bone-forming osteoblasts and cultures treated with β-gly-
cerophosphate, a TNAP substrate, did not calcify. Furthermore, TNAP inhibition had no eﬀect on VSMC calci-
ﬁcation. Although, VSMC calciﬁcation was associated with increased mRNA expression of osteoblast-related
genes (e.g. Runx2, osterix, osteocalcin, osteopontin), the relative expression of these genes was up to 40-fold
lower in calcifying VSMCs versus bone-forming osteoblasts. In summary, calcifying VSMCs in vitro display some
limited osteoblast-like characteristics but also diﬀer in several key respects: 1) their inability to form collagen-
containing bone; 2) their lack of reliance on TNAP to promote mineral deposition; and, 3) the deleterious eﬀect
of calciﬁcation on their viability.
1. Introduction
Vascular calciﬁcation is a common consequence of ageing, athero-
sclerosis, diabetes and chronic kidney disease. It is the pathological
deposition of calcium phosphate mineral, usually as hydroxyapatite, in
the medial and/or intimal layer of the arteries and heart valves. Arterial
medial calciﬁcation (AMC) refers to the calciﬁcation that occurs within
the tunica media of blood vessels and is characterised by increased
vessel stiﬀness and reduced blood ﬂow [1]. Traditionally, AMC was
thought to be a passive process caused by high serum levels of phos-
phate and calcium. However, it is now accepted that vascular calciﬁ-
cation is a complex cell-mediated process that is thought to share some
similarities with physiological bone formation [2]. Indeed, histological
analysis of calciﬁed arteries from patients with end stage renal disease
has shown the expression of several bone-associated proteins including
osteopontin (OPN), tissue non-speciﬁc alkaline phosphatase (TNAP)
and Runx2 [3,4].
The underlying factors which lead to the development of AMC are
multifaceted and not fully characterised. However, there has been sig-
niﬁcant advances in our understanding in recent years (see reviews
[5–8]). The structural protein which predominates in the medial layer
of blood vessels is elastin, and it is thought that these ﬁbres could act as
the nucleation site for calciﬁcation [9]. The predominant cell type
driving AMC is the vascular smooth muscle cell (VSMC) [10,11]. Under
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normal conditions, calciﬁcation is prevented by the actions of locally
produced (e.g. pyrophosphate) and circulating (e.g. fetuin A) inhibitors
[2]. However, when extracellular phosphate levels increase, VSMCs can
undergo a phenotypic transdiﬀerentiation to take on characteristics
usually associated with bone-forming osteoblasts [8,10,12]. These al-
tered VSMCs have been reported to express TNAP and other bone-re-
lated but not bone-speciﬁc proteins (e.g. OPN, COL1α1), and release
mineralisation-competent matrix vesicles [10,13,14]. Coupled with a
reduction in calciﬁcation inhibitors and increased VSMC apoptosis,
these changes can lead to the development of AMC [2,15].
One of the fundamental regulators of mineralisation is the ratio of
pyrophosphate to phosphate within the local environment [16]. Pyr-
ophosphate, which was identiﬁed as a key endogenous inhibitor of
biomineralisation in the 1960s [17], prevents crystal growth and re-
tards the conversion of amorphous calcium phosphates to crystalline
apatites. Pyrophosphate can be generated from nucleotide tripho-
sphates (such as ATP or UTP) by the actions of ecto-nucleotide pyr-
ophosphatase/phosphodiesterases (NPPs). NPPs display widespread
tissue expression and NPP1 in particular plays an important role in
regulating bone and soft tissue calciﬁcation [18,19]. TNAP is the key
enzyme involved in pyrophosphate breakdown [20]. Previous work has
shown that the opposing actions of NPP1 and TNAP are critical in de-
termining the extracellular phosphate/pyrophosphate ratio and, thus,
the level of skeletal mineralisation [20,21]. Increased TNAP expression
and activity combined with a decrease in NPP1 expression and activity
also play a role in the development of vascular calciﬁcation
[11,18,22–25].
Despite the reported similarities between AMC and bone formation
most in vitro studies only examine VSMCs in isolation using increased,
and often excessive, phosphate levels as the stimulus for calciﬁcation.
Furthermore, the classiﬁcation of a VSMC as an osteoblast-like cell is
often based upon the mRNA expression of osteogenic marker genes,
many of which are not unique to osteoblasts. This study used the well-
established primary mouse VSMC and osteoblast assays to directly
compare in vitro VSMC calciﬁcation and bone formation.
2. Methods
2.1. Reagents
All tissue culture reagents were purchased from Life Technologies
(Paisley, UK); unless mentioned, all chemicals were purchased from
Sigma Aldrich (Poole, UK). All primary antibodies were obtained from
Abcam UK (Cambridge, UK) and secondary antibodies from Jackson
Immuno Research Europe (Ely, UK).
2.2. Animals
Primary osteoblasts and VSMCs were isolated from C57BL/6J mice.
All procedures complied with the UK animals (Scientiﬁc Procedures)
Act 1986 and were reviewed and approved by the Royal Veterinary
College Research Ethics Committee.
2.3. Vascular smooth muscle cell (VSMC) calciﬁcation assay
Primary VSMCs were isolated from aortas of 6–8 week old mice.
After removal of the adventitia, the aorta was opened to expose the
endothelium under a dissection microscope. Tissues from 6 to 8 animals
were pooled and incubated with trypsin (0.25% w/v) for 10min to
remove any remaining adventitia and endothelium. Tissues were in-
cubated overnight in alpha Minimum Essential Medium, supplemented
with 10% foetal calf serum (FCS), 100U/ml penicillin, 100μg/ml
streptomycin and 0.25μg/ml amphotericin (complete mixture abbre-
viated to αMEM) before being digested with 425U/ml collagenase type
II (Worthington Biomedical Corporation, Lakewood, USA) for 5 h.
Isolated VSMCs were expanded in T25 tissue culture ﬂasks in a
humidiﬁed atmosphere of 5% CO2-95% air at 37 °C until conﬂuent.
Following seeding into 24-well plates, VSMCs were cultured in either
control medium (αMEM) or calcifying medium (αMEM+ 2 mM sodium
orthophosphate, 2–10 mM β-glycerophosphate or 1 mM β-glycer-
ophosphate/1 mM sodium diphosphate) for up to 14 days, with half
medium changes every 3 days. Medium pH was monitored throughout.
All experiments were performed on cells that were expanded and then
plated; cells were not passaged at any stage. Key, deﬁned time points
for calcifying VSMC cultures were: day 7 (onset of calciﬁcation), day 10
(sporadic calciﬁcation) and day 14 (widespread calciﬁcation).
2.4. Osteoblast bone formation assay
Osteoblasts were isolated from the calvariae of 3–5 day old mice by
trypsin/collagenase digestion as previously described [26–28]. Fol-
lowing isolation, cells were resuspended in αMEM and cultured for 2–4
days in a humidiﬁed atmosphere of 5% CO2-95% air at 37 °C in 75 cm2
ﬂasks until fully conﬂuent. Cells were sub-cultured into 6-well trays in
αMEM supplemented with 50 μg/ml ascorbic acid and 2mM β-glycer-
ophosphate or 1mM β-glycerophosphate/1 mM sodium diphosphate
and, with half medium changes every 3 days. Medium pH was mon-
itored throughout. All experiments were performed on cells that were
expanded and then plated; cells were not passaged at any stage. Deﬁned
time points for osteoblast cultures were day 4 (proliferating cells), day 7
(early osteoblasts), day 10 (mature osteoblasts) and day 14 (mature,
bone-forming osteoblasts).
2.5. Determination of VSMC calciﬁcation and bone formation
Calcifying VSMCs or bone-forming osteoblasts were washed twice
with phosphate buﬀered saline (PBS) and incubated with 0.6M HCl at
room temperature for 24 h. Calcium content was measured color-
imetrically by stable interaction with o-cresolphthalein using a com-
mercially available kit (Sigma-Adrich, Poole, UK) and corrected for
total protein concentration using the Bradford assay (Sigma-Aldrich,
Poole, UK). Bone formation in osteoblast cultures was also determined
using image analysis, as described previously [26,28]. Calcium de-
position was visualised by alizarin red staining of osteoblast/VSMC cell
layers, as previously described [28].
2.6. Staining for collagen and elastin deposition
Deposited collagen and elastin were visualised in osteoblasts and
control/calcifying VSMCs cultured for 7 and 14 days. Cells were ﬁxed
for 24 h in Bouin's solution before being stained using an Elastic Stain
kit (Sigma Aldrich, Poole, UK) as per manufacturer's instructions. The
presence of deposited elastic ﬁbres (black) and/or collagen ﬁbres (red)
was visualised by transmitted light microscopy.
2.7. Immunoﬂuorescence
Osteoblasts and VSMCs were seeded onto sterile 1 cm diameter
discs, cut from Melinex (Dupont Teijin Films, UK) clear polyester ﬁlm,
and cultured for up to 14 days. Upon termination, discs were ﬁxed with
4% paraformaldehyde in 0.1M phosphate buﬀer for 20min at room
temperature, washed 3× 5min with PBS and stored at 4 °C in PBS until
staining. Each disc was incubated with a blocking solution consisting of
2% BSA in PBS, for 1 h. Rabbit primary antibodies were diluted in
blocking solution at 1:500 (Col1α1) or 1:200 (SM22α). Discs were in-
cubated overnight in the primary antibody solution at 4 °C. Cells were
subjected to three 5min washes with PBS before incubation for 1 h with
the donkey anti-rabbit Cy3-labelled secondary antibody solution
(1:400), diluted in PBS with 1% BSA. After three further 5min PBS
washes, discs were mounted on to microscope slides using Prolong™
Diamond Antifade Mountant with DAPI (ThermoFisher Scientiﬁc, UK)
and viewed by ﬂuorescence microscopy (Cy3 absorbance and emission
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at 550 nm and 570 nm, respectively).
2.8. Elastin and collagen assays
Elastin and soluble collagen levels were investigated in control
VSMCs, calcifying VSMCs and osteoblasts after 7 and 14 days of culture.
To measure elastin, cell layers were treated with 0.25% trypsin for
10min to detach the cells. The resulting suspension was spun at
2,500 rpm for 5min to pellet the cells and associated proteins. Cell-
associated elastin was converted to water soluble α-elastin using 0.25M
oxalic acid and heating for 1 h at 100 °C. Elastin levels were measured
using the Fastin™ elastin assay (Biocolor Ltd, County Antrim, UK) ac-
cording to the manufacturer's instructions.
To measure soluble collagen, cells were transferred to αMEM con-
taining 5% FCS and the lysyl oxidase inhibitor β-aminoproponitrile
(50 μg/ml) for the ﬁnal 24 h of culture. The concentration of collagen
accumulated in the tissue culture medium was assayed using a Sirius
red dye-based kit (Sircol soluble collagen assay, Biocolor Ltd) according
to the manufacturer's instructions. For both assays, samples were nor-
malised to total cell protein using the Bradford assay (Sigma-Aldrich,
Poole, UK).
2.9. Transmission electron microscopy (TEM)
VSMCs and osteoblasts were seeded onto sterile 1 cm diameter discs,
cut from melinex clear polyester ﬁlm (Dupont Teijin Films, UK), and
cultured for 14 days in calcifying or non-calcifying conditions. Cells
were ﬁxed with fresh 2% glutaraldehyde/0.1 M sodium cacodylate for
48 h. Discs were rinsed with 0.1 M phosphate buﬀer and post-ﬁxed in
1% osmium tetroxide/1.5% potassium ferrocyanine in 0.1M sodium
cacodylate buﬀer. Specimens were dehydrated in a graded-ethanol
water series and inﬁltrated with Agar 100 resin. Ultra-thin sections
were cut at 70–80 nm using a diamond knife on a Reichert Ultracut E
microtome. Sections were collected on 300 mesh grids, counterstained
with lead citrate and viewed using a Joel 1010 transition electron mi-
croscope; images were recorded using a Gatan Orius CCD camera.
2.10. Determination of total TNAP and NPP activity
Enzyme activity was assessed in osteoblasts and VSMCs cultured for
14 days. TNAP activity was measured in cell lysates using a colorimetric
assay (Anaspec, CA, USA), as previously described [29]. TNAP activity
was normalised to cell protein using the Bradford assay (Sigma-Aldrich,
Poole, UK).
The assay to measure total cellular NPP activity was based on the
method originally described by Razzell and Khorana [30]. Brieﬂy, cells
were lysed in a buﬀer containing 1% Triton x 100 in 0.2 M Tris base
with 1.6mM MgCl2, pH 8.1. Following centrifugation at 500×g, the
NPP activity of collected supernatants was measured using 5mM p-
nitrophenyl-thymidine 5′-monophosphate as a substrate. Total protein
in cell lysates was determined using the Bradford assay (Sigma-Aldrich,
Poole, UK).
2.11. TNAP staining and inhibition
VSMCs (control and calcifying) and osteoblasts were cultured for 14
days before ﬁxation with 2.5% glutaraldehyde. Cell layers were ﬁxed to
demonstrate TNAP expression using a commercially available kit
(Sigma-Aldrich, Poole, UK). To determine the eﬀect of TNAP inhibition
on calciﬁcation and bone formation, calcifying VSMCs and osteoblasts
were cultured for 14 days with a 0.1–10 μM TNAP inhibitor
(CAS496014-13-2, Merck-Millipore, Watford, UK).
2.12. Cell number and viability assay
Cell number and viability were determined at regular intervals
during the culture period using the CytoTox 96® colorimetric cyto-
toxicity assay (Promega UK, Southampton UK), as described previously
[29]. Cell supernatants were collected to determine medium lactate
dehydrogenase (LDH) levels (cell viability). To establish total cellular
LDH levels, cells were lysed with 1% Triton X-100 in water for 1 h. The
LDH content of the supernatants and cell lysates were measured col-
orimetrically (490 nm) according to the manufacturer's instructions. A
standard curve for determination of cell numbers was constructed using
cells seeded at 102 to 106/well. Cell viability was calculated by ex-
pressing medium LDH as a percentage of the total cellular LDH/cell.
2.13. Quantiﬁcation of apoptosis by ﬂow cytometry
VSMCs plated in 24-well trays were cultured in control or calciﬁ-
cation medium for 7 days. Apoptosis was assessed via ﬂow cytometry
using an annexin V antibody conjugated to ﬂuorescein (Life
Technologies, Paisley, UK), as per manufacturer's instructions. Brieﬂy,
cells were detached using trypsin (0.25%) and the resultant pellet wa-
shed in ice cold PBS. This suspension was centrifuged and resuspended
in 1× annexin-binding buﬀer (Life Technologies, Paisley, UK). A
sample of this suspension was incubated with the annexin V antibody
for 15min and then analysed using a BD FACSCanto II Flow Cytometer
(Becton, Dickinson and Company, Oxford, UK). Data were processed to
calculate percentage apoptosis using Flowing Software (version 2.5.1)
(Turku University, Finland).
2.14. Total RNA extraction and DNase treatment
VSMCs (control and calcifying) and osteoblasts were cultured for 14
days before total RNA was extracted using TRIZOL® reagent (Invitrogen,
Paisley, UK) according to the manufacturer's instructions. Extracted
RNA was treated with RNase-free DNase I (35U/ml) for 30min at 37 °C.
The reaction was terminated by heat inactivation at 65 °C for 10min.
Total RNA was quantiﬁed spectrophotometrically by measuring ab-
sorbance at 260 nM. RNA was stored at −80 °C until ampliﬁcation by
qRT-PCR.
2.15. Quantitative real time polymerase chain reaction (qRT-PCR)
VSMC and osteoblast RNA (50 ng) was transcribed and ampliﬁed
using the qPCRBIO SyGreen one-step qRT-PCR kit (PCR Biosystems,
London, UK), which allows cDNA synthesis and PCR ampliﬁcation to be
carried out sequentially. qRT-PCR was performed according to manu-
facturer's instructions with initial cDNA synthesis (45 °C for 10min) and
reverse transcriptase inactivation (95 °C for 2min) followed by 40 cy-
cles of denaturation (95 °C for 5 s) and detection (60 °C for 30 s). All
reactions were carried out in triplicate using RNAs derived from 4
diﬀerent cultures. Primers sequences (forward/reverse): β-actin, S: gcc
ttc ctt cct ggg tat gg/AS: tcc gat tca act cat act gc; Collagen type 1 alpha
chain 1 (Col1α1): S: ggg aca cag agg ttt cag tgg/AS: agc tcc att ttc acc agg
act g; TNAP (Alpl), S: aaa cct aga cac aag cac tc/AS: tcc gat tca act cat act
gc; Osteocalcin (Bglap2), S: gca gac acc atg agg acc ct/AS: gca gct tgt gcc
gtc cat ac; Osterix(Sp7), S: aga gat ctg agc tgg gta gag g/AS: aag aga gcc tgg
caa gag g; OPN (Spp1), S: gag agc cag gag agt gcc ga/AS: gct ttg gaa ctt gct
tga cta tcg; Runx2, S: acc ata aca gtc ttc aca aat cct/AS: cag gcg atc aga gaa
caa act a; Sm22α, S: tcc agt cca caa acg acc aag c/AS: gaa ttg agc cac ctg ttc
cat ctg;Myosin heavy chain (Myh10), S: atc aag cag ctt cgc aaa c/AS: tcg
agc ctc ttc tag ttc acg; Caldesmon 1 (Cald1), S: cag ctg cgg aca tgc tta g/
AS: cgt cat cat cat ttc tct gat agg; Smoothelin (Smtn), S: ccg acc aaa cta aca
cga aac/AS: act cag aat tcc tga cat gtg g; α-Smooth muscle actin (Acta2),
S: ctc tct tcc agc cat ctt tca t/AS: tat agg tgg ttt cgt gga tgc; Elastin, S: tgg agc
agg act tgg agg t/AS: cct cca gca cca tac tta gca.
2.16. Western blot
Protein was extracted from VSMCs (in control and calciﬁcation
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medium) and osteoblasts at 4, 7 and 14 days. Cell layers were lysed in
ice-cold radio immunoprecipitation (RIPA) lysis buﬀer (50mM Tris HCl
pH 7.4, 150mM NaCl, 5 mM EDTA, 0.1% SDS 1mM phenyl methyl
sulfonyl ﬂuoride (PMSF), 1 mg/ml aprotinin, 1 mM Na3VO4 and
2.5 mg/ml deoxicolic acid). Cell homogenates were sonicated for 5 min
and stored at −80 °C for at least half an hour before use. Protein
concentrations from lysates were determined using the Bradford assay
(Sigma-Aldrich, Poole, UK). Prior to loading total protein samples were
denatured by incubating at 95 °C for 5 min in the presence of 5× re-
ducing sample buﬀer (60 mM Tris-HCl pH 6.8, 25% glycerol, 2% SDS,
10% β-mercaptoethanol and 0.1% bromophenol blue). Protein samples
(20μg/lane) were loaded into SDS-PAGE (10%) gels and transferred
onto a polyvinylideniﬂuoride (PVDF) membrane (Amersham,
Buckinghamshire, UK) by the use of a wet tank blotter (Bio-Rad,
Watford, UK) at 150 V for 1 h. Membranes were then blocked with 5%
non-fat milk and incubated with β-actin (1:1000), Runx2 (1:500), OPN
(1:200), SM22α (1:200) or Acta2 (1:500) antibodies overnight at 4 °C.
After washing, blots were incubated in horseradish peroxidase-con-
jugated secondary antibodies for 1 h at room temperature. A peroxidase
detection system (Immobilon™ Western, Merck-Millipore, Watford UK)
and ChemiDoc™ XRS + system (Bio-Rad, Watford, UK) was used for the
visualisation of immunoreactivity.
2.17. Measurement of ATP release
Basal ATP release from VSMCs was measured at 4, 7, 10 and 14 days
of culture and from osteoblasts at day 14 of culture. Prior to mea-
surement of ATP release, culture medium was removed, cell layers
washed and cells incubated with serum-free DMEM. To measure basal
ATP release, samples were collected after 1 h and immediately mea-
sured using the luciferin-luciferase assay as described previously [31].
2.18. Statistical analysis
Data were analysed using GraphPad Prism 7 software (San Diego,
CA). Statistical comparisons were made using a T-test or a one-way
analysis of variance (ANOVA) with a post-hoc Bonferroni correction for
multiple comparisons. Results are expressed as means ± SEM for 6–12
replicates. Results are representative of experiments performed at least
three times using cells obtained from diﬀerent animal isolations.
3. Results
3.1. The morphology of in vitro VSMC calciﬁcation diﬀers from that of bone
formation by osteoblasts
Examination of cultures by light microscopy demonstrated that os-
teoblasts reproducibly formed abundant, large mineralised bone no-
dules when cultured with 2mM β-glycerophosphate. These bone
structures stain strongly with alizarin red and are often associated with
regions of unmineralised collagenous matrix (Fig. 1A). However, ex-
cessive levels of β-glycerophosphate (10mM) resulted in non-speciﬁc
mineral deposition that is not true bone formation (Fig. 1B). Control
VSMCs were densely packed but displayed no signs of calciﬁcation
(Fig. 1C). VSMCs treated with 2mM or 10mM β-glycerophosphate for
14 days did not calcify (Fig. 1D and E). VSMCs cultured with 2mM
sodium orthophosphate formed discrete regions of calciﬁcation that
were much smaller than osteoblast bone nodules and did not appear to
be associated with collagenous matrix (Fig. 1F). In osteoblasts, sodium
orthophosphate also resulted in some non-speciﬁc mineral deposition
(Fig. 1G). Assessment of culture medium pH revealed no signiﬁcant
diﬀerences between the diﬀerent conditions: 2 mM β-glycerophosphate
(osteoblasts = pH 7.48 ± 0.01, VSMCs= pH 7.49 ± 0.01), 10mM β-
glycerophosphate (osteoblasts = pH 7.47 ± 0.02, VSMCs= pH
7.46 ± 0.01), sodium orthophosphate (osteoblasts = pH 7.48 ± 0.03,
VSMCs= pH 7.48 ± 0.03) and control VSMCs (pH 7.49 ± 0.01).
To ensure that results were not confounded by non-cell mediated
calciﬁcation processes, unless stated, for all subsequent experiments
osteoblasts were cultured in 2mM β-glycerophosphate and calcifying
VSMCs refers to cells cultured with 2mM sodium orthophosphate. The
overall quantity of deposited calcium, as assessed by colorimetric assay,
was similar in bone-forming osteoblasts and calcifying VSMCs
(Fig. 1H).
3.2. Collagen production by osteoblasts and VSMCs
Deposition of collagen ﬁbres (red) was visible in both early osteo-
blast (day 7) and mature, bone-forming osteoblast (day 14) cultures. By
day 14, extensive mineralisation of the organic matrix had occurred;
collagen ﬁbres showed as regions of red staining underneath the de-
posited bone mineral (dark brown/black) (Fig. 2A). There was no ob-
vious deposition of collagen ﬁbres in control or calcifying VSMCs at any
stage via light microscopy (Fig. 2A). Immunoﬂuoresecent staining for
Col1α1 showed extensive protein expression in and around osteoblasts
(Fig. 2A). Control and calcifying VSMCs also displayed Col1α1 ex-
pression; however, immunostaining was usually cell associated and
much less widespread than in osteoblasts (Fig. 2A). Control staining for
SM22α showed uniform expression across the cell layers in both VSMC
and osteoblast cultures (Fig. 2A).
Analysis of Col1α1 mRNA levels (day 14 of culture) showed that
gene expression was up to 11-fold lower in control and calcifying
VSMCs, relative to bone forming osteoblasts (Fig. 2B). Osteoblast dif-
ferentiation and bone formation were associated with increased levels
of soluble collagen. In contrast, no soluble collagen was detected in
cultures of control or calcifying VSMCs (Fig. 2C).
3.3. Production of elastin by cultured VSMCs and osteoblasts
There was no obvious discrete staining of elastin ﬁbres (black)
evident in osteoblast, control or calcifying VSMCs at any stage
(Fig. 2A). However, large regions of dark brown/black staining, which
corresponded to the areas of calciﬁcation, were observed in osteoblasts
and calcifying VSMCs. Analysis of elastin mRNA levels (day 14 of cul-
ture) showed that gene expression was ∼2-fold higher in control
VSMCs, relative to bone-forming osteoblasts and calcifying VSMCs
(Fig. 2D). Cell-associated elastin was detected in control VSMCs, cal-
cifying VSMCs and osteoblasts at all stages (Fig. 2E). Consistent with
the mRNA expression, control VSMCs displayed higher elastin levels
(≤50%) than osteoblasts and calcifying VSMCs at day 14; no diﬀer-
ences were observed at day 7 (Fig. 2E).
3.4. Marked diﬀerences in the ultrastructure of VSMC calciﬁcation and the
mineralised bone nodules formed by osteoblasts
TEM imaging of early osteoblasts showed no evidence of bone for-
mation (Fig. 3A). Clear extracellular deposition of collagen ﬁbres and
widespread mineralised matrix (Fig. 3C and E) were evident in mature,
bone-forming osteoblasts. The banding pattern typically associated
with collagen ﬁbres was clearly visible within the mineralised bone
nodule (Fig. 3E). No calciﬁcation was observed in VSMCs grown under
basal conditions (Fig. 3B). In cultures of calcifying VSMCs, there were
no collagen ﬁbres, however, deposits of ﬁlamentous cellular debris
were observed (Fig. 3D and F). VSMC calciﬁcation typically occurred as
small discrete regions sometimes associated with cellular debris
(Fig. 3F). Comparatively, osteoblast-mediated bone mineralisation was
denser, larger and more widespread than the calciﬁcation in VSMC
cultures (Fig. 3E and F). In bone-forming osteoblasts, matrix vesicles
were observed in association with deposited collagen ﬁbres, whilst
cultures of calcifying VSMCs contained smaller extracellular vesicles
that were often associated with the ﬁlamentous cellular debris (Fig. 3G
and H).
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3.5. TNAP activity is 100-fold higher in bone-forming osteoblasts than
calcifying VSMCs
Bone-forming osteoblasts showed strong expression of TNAP, par-
ticularly in the cells surrounding the bone nodules (Fig. 4A). In con-
trast, calcifying VSMCs displayed limited, diﬀuse staining for TNAP
(Fig. 4A). No obvious TNAP staining was evident in cultures of control
VSMCs (Fig. 4A). The rank order for TNAP activity was bone-forming
osteoblasts > > >calcifying VSMCs > control VSMCs (Fig. 4B);
VSMCs displayed a very low level of enzyme activity relative to os-
teoblasts (at least 100-fold lower). Basal TNAP activity was 50% higher
in calcifying VSMCs (2.85 ± 0.1 units/min/μg) compared to control
VSMCs (≤1.84 ± 0.1 units/min/μg) (Fig. 4B).
The TNAP inhibitor (CAS496014-13-2) concentration-dependently
(≥0.1 μM) reduced bone formation by up to 90% (Fig. 4D). In contrast,
culture of VSMCs with the same TNAP inhibitor had no eﬀect on the
level of calciﬁcation (Fig. 4E).
3.6. VSMCs display higher total NPP activity than osteoblasts
Rank order of total NPP activity was control VSMCs > calcifying
VSMCs > bone-forming osteoblasts (Fig. 4C). NPP activity in calci-
fying VSMCs was 3-fold lower than control VSMCs. Osteoblast total NPP
activity was 3.4-fold and 11-fold lower than calcifying and control
VSMCs, respectively (Fig. 4C).
3.7. Cell number and viability are reduced in calcifying VSMCs but not in
bone-forming osteoblasts
Both cell types progressively increased in number as the culture
progressed; osteoblasts showed the largest increase in cell number over
time (Fig. 5A). At day 4, 7 and 10 there were no diﬀerences in control
Fig. 1. Comparison of in vitro bone formation and VSMC calciﬁcation. Representative phase contrast microscopy images (alizarin red stained) and whole well scans
(unstained) of osteoblast and VSMCs after 14 days in culture. (A) Abundant formation of mineralised bone nodules by primary osteoblasts cultured with 2mM β-
glycerophosphate; unmineralised deposited collagen is highlighted by the arrow. (B) Widespread, non-speciﬁc mineral deposition was observed in osteoblasts
cultured with 10mM β-glycerophosphate (highlighted by the arrow). (C) No calciﬁcation in control VSMC cultures. VSMCs cultured with (D) 2mM and (E) 10mM β-
glycerophosphate for 14 days do not calcify. (F) VSMCs grown in 2mM sodium orthophosphate form small, discrete regions of calciﬁcation. These structures are
signiﬁcantly smaller than osteoblast bone nodules and are less visible in the whole well scans. (G) Osteoblasts cultured with sodium orthophosphate also display non-
speciﬁc mineral deposition (white arrow). Scale bars: phase contrast microscopy images= 250 μm, tissue culture wells= 0.5 cm. (H) The overall level of deposited
calcium was similar in cultures of bone-forming osteoblasts and calcifying VSMCs (2mM phosphate) but ∼90% lower in control VSMCs. Values are mean ± SEM
(n = 6 replicate wells), *** = p < 0.001.
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Fig. 2. Collagen and elastin production by osteoblasts and VSMCs. (A) Osteoblasts and VSMCs were cultured for 7 or 14 days and then stained to visualise collagen (red)
and elastin (black) ﬁbres. Representative light microscopy images showing widespread deposition of collagen (highlighted by the arrows) in early and mature, bone-
forming osteoblasts. Mineralised matrix in bone-forming cultures stained dark brown/black and was associated with collagen staining. No obvious collagen or elastin
staining in control VSMCs or calcifying VSMCs via light microscopy. Regions of calciﬁcation in VSMC cultures also stained dark brown/black (highlighted by the
arrows). Immunoﬂuorescent staining for Col1α1 showed extensive collagen expression and deposition in osteoblast cultures. Control and calcifying VSMCs also
expressed Col1α1 protein but immunostaining was primarily cell associated rather than extracellular. Staining for SM22α showed uniform expression across os-
teoblast and VSMC cell layers. Scale bars, light microscopy= 50 μm, immunoﬂuorescence= 50 μm. (B) Col1α1 mRNA expression was up to 11-fold lower in control
and calcifying VSMCs, relative to bone-forming osteoblasts. (C) Soluble collagen levels increased with osteoblast diﬀerentiation and bone formation (black bar). No
soluble collagen was detected in control and calcifying VSMC cultures [ND=not detected]. (D) Elastin mRNA expression was∼2-fold higher in control VSMCs than
bone-forming osteoblasts; calcifying VSMCs and osteoblasts displayed similar levels of elastin expression. (E) Cell-associated elastin was up to 50% higher in control
VSMCs compare to calcifying VSMCs and osteoblasts. Values are mean ± SEM (n=6 replicate wells, n = 4 RNA sets), * = p < 0.05, *** = p < 0.001.
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and calcifying VSMC number; at day 14, cell number was 12% lower in
calcifying VSMCs (Fig. 5A). Increasing culture time was also associated
with a progressive reduction in viability (shown as percentage of dead
cells) of calcifying VSMCs; osteoblast and control VSMC viability was
unchanged (Fig. 5B). The percentage of dead cells was up to 7-fold
higher in calcifying VSMCs than bone-forming osteoblasts and control
VSMCs (Fig. 5B). The level of apoptosis was nearly doubled in calci-
fying VSMCs compared to control cells after 7 days in culture (Fig. 5C).
For comparison, osteoblasts were also cultured in conditions associated
with dystrophic mineral deposition (10 mM β-glycerophosphate or
2 mM sodium orthophosphate); these cells displayed reduced viability
compared to osteoblasts grown in optimal conditions for regulated bone
formation (+2 mM β-glycerophosphate) (Fig. 5D).
3.8. Comparison of marker gene expression between VSMCs and bone-
forming osteoblasts
mRNA expression of typical osteoblast (Runx2, Sp7, Alpl, Spp1,
Bglap2) and VSMC (Sm22α, Myh10, Acta2, Cald1, Smtn) markers was
investigated in control VSMCs, calcifying VSMCs and bone-forming
osteoblasts after 14 days of culture. Data are presented as the fold
change in mRNA expression relative to that seen in bone-forming os-
teoblasts (Fig. 6A and B).
Previous work has shown that VSMC calciﬁcation is associated with
an increase in expression of osteoblast markers [10,13]. Consistent with
this, we found that expression of Runx2, Sp7, Alpl, Bglap2 and Spp1 was
increased up to 6-fold in calcifying VSMCs compared to control VSMCs
(Fig. 6A). However, in all cases mRNA levels were signiﬁcantly lower in
VSMCs than in mature, bone-forming osteoblasts. Expression of Runx2
Fig. 3. Diﬀerences in the ultrastructure of
VSMC calciﬁcation and the mineralised bone
nodules formed by osteoblasts. Cultures of (A)
early osteoblasts and (B) non-calcifying
VSMCs showed no evidence of any extra-
cellular mineralisation. (C) In bone-forming
osteoblasts there was widespread collagen
[COL] deposition and clear mineralised
matrix which formed part of a bone nodule
[BN]. (D) Cultures of calcifying VSMCs
contained amorphous regions of calciﬁca-
tion [Cal] and extracellular ﬁbril-like struc-
tures that appeared to be cellular debris
[CD] but no deposited collagen ﬁbres. (E)
Higher power images showed that miner-
alised matrix [MM] was formed in and
around the collagen ﬁbres [COL] in bone-
forming osteoblasts. (F) The extracellular
calciﬁcation [Cal] present in VSMCs was less
widespread, morphologically distinct from
the osteoblast bone nodules and was some-
times associated with ﬁlamentous cellular
debris [CD]. (G) In osteoblasts, matrix ve-
sicles [MV] were seen associated with col-
lagen ﬁbres [COL]. (H) In calcifying VSMCs,
extracellular vesicles [EV] were observed
associated with ﬁlamentous cellular debris
[CD]. Images shown are representative of
the calciﬁcation and matrix deposition ob-
served in three diﬀerent cell preparations.
Scale bars: A-B= 5 μm, C-D=2 μm, E-
F=1 μm, G-H=200 nm.
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and Sp7 (early osteoblast markers) was up to 12-fold lower in control
VSMCs and 3-fold lower in calcifying VSMCs compared to osteoblasts.
Control VSMCs showed very limited expression of mature osteoblast
marker genes (Alpl, Bglap2, Spp1) with mRNA levels up to 120-fold
lower than that seen in bone-forming osteoblasts. Expression levels of
these genes increased when VSMCs began to calcify but remained up to
40-fold lower than in osteoblasts (Fig. 6A).
Bone-forming osteoblasts were found to express mRNA for all the
VSMC marker genes studied (Fig. 6B). Of these, only Cald1, Myh10 and
Smtn were expressed at a higher level in VSMCs than osteoblasts. Ex-
pression of Sm22α and Acta2 was at a similar level in control VSMCs but
up to 4-fold lower in calcifying VSMCs (compared to osteoblasts)
(Fig. 6B).
3.9. Comparison of protein expression in osteoblasts and VSMCs
Changes in the protein expression of osteoblast (Runx2, OPN) and
VSMC genes (Sm22α, Acta2) were investigated in osteoblasts and
VSMCs. After 7 and 14 days of culture, levels of Sm22α were lower in
calcifying VSMCs compared to control VSMCs (Fig. 6C). Calciﬁcation
had less of an eﬀect on Acta2 protein expression with only a small
decrease at day 14. Osteoblasts also displayed strong expression of
these proteins with Sm22α levels, in particular, being higher in osteo-
blasts than VSMCs. Furthermore, cellular diﬀerentiation appeared to
inﬂuence osteoblast Sm22α expression since the highest levels were
seen in proliferating cells (day 4) (Fig. 6C).
The transcription factor, Runx2, is considered an early osteoblast
marker whilst OPN is a marker of more mature, bone-forming cells.
Runx2 protein expression was detected in osteoblasts, control and cal-
cifying VSMCS but, in keeping with the mRNA data, the levels were
higher in osteoblasts (at all stages of diﬀerentiation). Interestingly,
Runx2 expression was fairly similar in calcifying and control cells
(Fig. 6C). OPN expression increased with osteoblast diﬀerentiation with
the highest levels in mature, bone-forming cells. At day 7, control and
calcifying VSMCs showed no OPN protein expression; however, low
OPN expression was evident in calcifying VSMCs at day 14 (Fig. 6C).
3.10. Release of the mineralisation inhibitor, ATP, by osteoblasts and
VSMCs
ATP is an extracellular signalling molecule and a substrate for a
range of ecto-nucleotidases including NPP1. Side-by-side comparison
after 14 days in culture showed that rank order of ATP release per cell
was bone-forming osteoblast > calcifying VSMCs > control VSMCs;
osteoblasts released 2.4-fold and 4.3-fold more ATP than calcifying and
control VSMCs, respectively (Fig. 7A). Throughout the culture period,
the extracellular ATP levels were up to 85% higher in calcifying VSMCs
compared to control VSMCs (Fig. 7B).
Fig. 4. TNAP activity is 100-fold higher in bone forming osteoblasts than calcifying VSMCs. (A) Representative whole well scans and phase contrast microscopy images of
osteoblasts and VSMCs stained to visualise TNAP expression. Bone-forming osteoblasts displayed the highest level of TNAP expression with only limited staining in
calcifying VSMCs (highlighted by the arrow). No obvious TNAP staining was observed in control VSMCs. Scale bars: phase contrast microscopy images= 250 μm,
tissue culture wells= 0.5 cm. (B) Rank order of TNAP activity was bone-forming osteoblasts> > >calcifying VSMCs > control VSMCs. TNAP activity was 50%
higher in calcifying VSMCs compared to control VSMCs. (C) Rank order of total NPP activity was control VSMCs > calcifying VSMCs > bone-forming osteoblasts.
(D) Culture with a TNAP inhibitor (≥0.1 μM) reduced bone formation by up to 90%. (E) Inhibition of TNAP had no eﬀect on VSMC calciﬁcation. Values are
mean ± SEM (n = 6 replicate wells), *** = p < 0.001.
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3.11. Identiﬁcation of a ‘universal’ mineralisation medium for osteoblastic
bone formation and VSMC calciﬁcation
One potential limitation of the results described above is that they
use slightly diﬀerent tissue culture conditions to induce bone miner-
alisation/VSMC calciﬁcation (i.e. the form of phosphate used). To verify
that the eﬀects observed here were due to fundamental diﬀerences in
the cells rather than the form of phosphate added, we identiﬁed con-
ditions that could induce regulated bone formation and VSMC calciﬁ-
cation. Culture of cells in medium supplemented with 1 mM β-glycer-
ophosphate and 1 mM sodium diphosphate (1 + 1 conditions) resulted
in selective mineralisation of the collagenous matrix in osteoblasts and
the formation of small regions of calciﬁcation in VSMCs (Fig. 8A). For
both cell types, the calciﬁcation formed displayed a similar morphology
to that seen in osteoblasts and VSMCs cultured in the original condi-
tions (Fig. 1A and F). The level of TNAP and Col1α1 staining and the
appearance of the calciﬁcation under TEM also strongly resembled that
observed with the original conditions (Fig. 8A).
The diﬀerent cell culture conditions had no eﬀect on the overall
level of mineralised bone nodule formation (Fig. 8B), whilst the level of
VSMC calciﬁcation was increased by 40% in the 1 + 1 conditions
(Fig. 8C). Key parameters such as cell number (Fig. 8D), cell viability
(Fig. 8E), ATP release (Fig. 8F) and TNAP activity (Fig. 8G) were un-
changed. Furthermore, in all cases the diﬀerences between mineralising
osteoblasts and calcifying VSMC were still observed.
4. Discussion
The development of AMC is widely accepted to be associated with a
phenotypic transdiﬀerentiation of VSMCs which results in them taking
on characteristics usually associated with bone-forming osteoblasts
[2,8,10,12]. The culture of VSMCs in a calcifying (high phosphate)
environment is widely used to study the pathogenesis of AMC in vitro.
This investigation directly compared this model of AMC with the es-
tablished and extensively used osteoblast bone formation assay
[26–28]. It also sought to develop a ‘universal’ calciﬁcation medium
which allowed the direct comparison of both processes. We found that,
compared to control VSMCs, calcifying VSMCs exhibit some limited
osteoblast-like characteristics. However, they diﬀer to mature osteo-
blasts in a number of key ways including: 1) their failure to form
Fig. 5. Reduced cell viability and number in calcifying
VSMCs. (A) All cells showed an increase in number
with increasing time in culture. Cell number was
unchanged at day 4, 7 and 10 but was decreased 12%
at day 14 in calcifying VSMCs compared to control
VSMCs. (B) Increasing culture time was associated
with a progressive reduction in calcifying VSMC cell
viability; the percentage of dead cells was up to 7-
fold higher in calcifying VSMCs compared to bone-
forming osteoblasts and control VSMCs. (C) At day 7,
the level of apoptosis was almost doubled in calci-
fying VSMCs compared to control cells. (D) Reduced
viability in osteoblasts grown in medium associated
with dystrophic mineral deposition. Values are
mean ± SEM (n = 6 replicate wells),
*** = p < 0.001, * = p < 0.05.
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collagen-containing bone; 2) their lack of reliance on TNAP to promote
mineral deposition; and, 3) the negative eﬀect of calciﬁcation on their
survival. Our study shows that development of VSMC calciﬁcation in
vitro is a process distinct from the bone nodule formation performed by
cultured osteoblasts. Furthermore, calcifying VSMCs appear to have a
transitional phenotype that lies somewhere between that of a normal
VSMC and a mature, bone-forming osteoblast.
VSMC calciﬁcation and mineralised bone nodule formation are the
commonly used experimental end points for studying AMC and osteo-
genesis, respectively, in vitro. This investigation clearly shows that,
when cultured with physiologically relevant levels of phosphate (i.e.
≤3mM), these processes diﬀer signiﬁcantly. The data presented in
Figs. 1–3, and also in many other studies [26,28,32], show that osteo-
blasts secrete and deposit signiﬁcant amounts of collagenous matrix
which is then mineralised to form large “trabecular-shaped” bone no-
dules in vitro. In contrast, culture of VSMCs in phosphate-containing
medium led to the formation of numerous small regions of calciﬁcation
that were not obviously associated with extracellular matrix. High
power imaging using TEM revealed that this calciﬁcation was fre-
quently located on and around ﬁlamentous cellular debris rather than
collagen ﬁbres. Further analysis of collagen production showed that
both cell types expressed Col1α1 mRNA and protein. In the case of
VSMCs, and consistent with earlier work [33], Col1α1 expression was
primarily localised in or on the surface of cells. Whilst clearly expressed
by VSMCs, no soluble collagen was detected in the culture medium and
no deposited collagen ﬁbres were evident in the TEM images. This in-
dicates that VSMCs are not exporting and depositing collagen into the
extracellular environment in the same manner as osteoblasts. However,
this lack of reliance on collagen for in vitro VSMC calciﬁcation is in
contrast to a recent study which implicated the collagen cross-linking
factors, LOX and PLOD, in the development of AMC [34]. Cell asso-
ciated elastin was detected in both VSMCs and osteoblasts with the
highest level seen in control, non-calcifying VSMCs. The observed de-
crease in elastin production in calcifying VSMCs compared to control
cells is consistent with earlier studies which have associated AMC with
a loss of elastin [35,36]. Taken together, these data show that the ex-
tracellular matrix produced by cultured VSMCs in vitro diﬀers con-
siderably in composition, abundance and structure to that which is
secreted by bone-forming osteoblasts.
Earlier work has linked the initiation of AMC with increased VSMC
apoptosis [15,37,38]. Although mechanistically not fully deﬁned, it is
thought that a calcifying environment can induce apoptosis and the
Fig. 6. Comparison of marker gene expres-
sion in osteoblasts and VSMCs. (A)
Expression of Runx2, Sp7, Alpl, Bglap2 and
Spp1 was increased in calcifying VSMCs
compared to control VSMCs but, in all cases,
mRNA expression levels were lower in
VSMCs than osteoblasts. (B) Osteoblasts
express mRNA for all the VSMC marker
genes studied. Only Cald1, Myh10 and Smtn
were expressed at a higher level in VSMCs
than osteoblasts. mRNA expression is pre-
sented as the fold change in VSMC expres-
sion relative to bone-forming osteoblasts.
Values are mean ± SEM (n = 4 RNA sets),
*** = p < 0.001, ** = p < 0.01
* = p < 0.05. (C) Protein expression of
Sm22α was lower in calcifying VSMCs
compared to control VSMCs at both day 7
and 14; calciﬁcation had a limited eﬀect on
Acta2 levels. Osteoblasts also displayed
strong expression of these proteins with
Sm22α expression being higher in osteo-
blasts than VSMCs. Runx2 was detected in
osteoblasts, control and calcifying VSMCs
with the highest levels being seen in osteo-
blasts. OPN protein was expressed at all
stages of osteoblast diﬀerentiation but pro-
tein levels were highest in mature, miner-
alising osteoblasts. OPN protein was only
evident in calcifying VSMCs at day 14. Blots
shown are representative of experiments
performed 3 times with diﬀerent protein
sets.
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VSMC-derived apoptotic bodies can then act as nucleation sites for
hydroxyapatite crystal formation [15]. Consistent with these observa-
tions, we found that VSMC calciﬁcation was associated with higher
levels of cell death and apoptosis compared to control VSMCs. The in-
crease in calcifying VSMC apoptosis was measured after 7 days in
culture, at this point the level of calciﬁcation is still fairly low and any
changes in gene expression are less pronounced. This further supports
the notion that increased apoptosis is one of the early events in the
development of AMC. Earlier studies have also shown that inhibiting
apoptosis can lead to a reduction in AMC [38,39]. In agreement, we
have previously demonstrated that extracellular ATP and UTP can in-
hibit VSMC calciﬁcation by up to 80%, a protective eﬀect that is
mediated via the prevention of calciﬁcation-induced apoptosis [40].
However, since extracellular nucleotides do not fully block calciﬁca-
tion, these ﬁndings also suggest that increased apoptosis is not the only
factor driving the development of VSMC calciﬁcation in this experi-
mental model.
In contrast, physiological bone formation is not associated with
signiﬁcant osteoblast cell death. Consistent with this, the viability of
actively mineralising osteoblasts remained unchanged when cells were
grown in optimal conditions for bone formation. Bone mineralisation is
instead initiated within matrix vesicles where the coordinated actions
of enzymes and proteins allow regulated hydroxyapatite formation
without cell death [41,42]. Matrix vesicles associated with collagen
ﬁbres were evident in our bone-forming osteoblast cultures. AMC has
also been linked with the release of mineralisation-competent extra-
cellular vesicles [14]. Consistent with these ﬁndings, we observed ex-
tracellular vesicles associated with ﬁlamentous cellular debris. To-
gether, these data suggest that the processes which drive the initiation
of calciﬁcation in AMC are much more heterogeneous than those in
bone mineralisation. Thus, the dissimilar appearance of VSMC calciﬁ-
cation and mineralised bone nodules in vitro could reﬂect diﬀerences in
both the extracellular matrix and the events which initiate calciﬁcation.
Bone mineralisation is a tightly regulated process that involves the
coordinated activity of TNAP and NPP1 to control the phosphate/pyr-
ophosphate ratio [20,21]. AMC has been associated with an increase in
VSMC TNAP expression and activity [11,23,43]. Our data show that a
high phosphate environment increases VSMC TNAP expression and
activity to some extent. However, calcifying VSMCs still displayed le-
vels of TNAP activity that were up to 100-fold lower than those ob-
served in bone-forming osteoblasts. Furthermore, β-glycerophosphate
(2–10mM), which is hydrolysed by TNAP to produce phosphate, did
not induce VSMC calciﬁcation within 14 days (unlike phosphate).
Culture with a TNAP inhibitor also had no eﬀect on the level of calci-
ﬁcation. This observation is in agreement with earlier studies which
showed no eﬀect of TNAP inhibition on calciﬁcation [44,45] but is in
contrast to other investigations which reported that blocking TNAP
activity can reduce calciﬁcation [46,47]. The reasons for this dis-
crepancy between investigations is unclear but may be related to the
experimental approaches used. In particular, many studies use the non-
selective compound Levamisole to reduce TNAP activity, here we used
the more potent and selective TNAP inhibitor (CAS496014-13-2) [48].
The eﬀectiveness of this compound is highlighted by the clear, dose-
dependent inhibition of mineralised bone nodule formation in osteo-
blast cultures (Fig. 4E). Taken together our ﬁndings suggest that, unlike
in osteoblasts, TNAP does not play a signiﬁcant role in mediating VSMC
calciﬁcation in vitro. Interestingly, we have also shown that extra-
cellular ATP, at a concentration that inhibits VSMC calciﬁcation by up
to 90%, actually causes a counter-intuitive increase in TNAP activity
[40]. Therefore it is clear, that the exact role of TNAP in driving the
development of VSMC calciﬁcation in vitro requires further clariﬁca-
tion.
Under normal physiological conditions, VSMCs can prevent tissue
calciﬁcation by producing local inhibitors such as pyrophosphate [2].
Previous studies have shown that development of AMC is associated
with a decrease in NPP1 activity [18,24,25]. Consistent with this, we
found that control VSMCs displayed the highest level of total NPP ac-
tivity and calciﬁcation was associated with a loss of enzyme activity.
It has been reported that calcifying VSMCs undergo a phenotypic
transdiﬀerentiation to become more osteoblast-like [10,12]. These
changes have been associated with increased expression of typical os-
teoblast genes (e.g. Runx2, Alpl (TNAP), Bgalp2 (OCN), Spp1 (OPN)) and
decreased expression of VSMC genes (e.g. Sm22α, Acta2) [10,12]. This
study directly compared the relative levels of gene expression between
mature, bone-forming osteoblasts, control VSMCs and calcifying VSMCs
for the ﬁrst time. An increase in osteogenic gene expression in calci-
fying VSMCs was observed in this study; however, the relative levels of
mRNA expression remained signiﬁcantly lower in calcifying VSMCs
than osteoblasts. Markers of the mature osteoblast phenotype such as
Alpl, Bgalp2 and Spp1 showed particularly limited expression. The low
mRNA levels of these genes suggests that, even when there is wide-
spread calciﬁcation, calcifying VSMCs are only at the early stages of
Fig. 7. Release of the mineralisation inhibitor, ATP, by osteo-
blasts and VSMCs. (A) Rank order of ATP release per cell was
bone-forming osteoblasts > calcifying VSMCs > control
VSMCs. Osteoblasts released 2.4-fold and 4.3-fold more ATP
than calcifying and control VSMCs, respectively. (B) Basal
ATP release was up to 85% higher in calcifying VSMCs
compared to control VSMCs. Values are mean ± SEM
(n= 12 replicate wells), *** = p < 0.001, * = p < 0.05.
J.J. Patel, et al. Experimental Cell Research 380 (2019) 100–113
110
diﬀerentiating towards an osteoblast-like lineage.
VSMCs show a high degree of plasticity and therefore many genes
are used as markers of the cell phenotype including Sm22α, Acta2,
Cald1, Myh10 and Smtn [49,50]. In broad agreement to earlier work, we
observed decreased levels of Sm22α, Acta2 and Cald1 mRNA in calci-
fying VSMCs. Somewhat surprisingly, we found that bone-forming
osteoblasts also expressed mRNA for all of the VSMC genes studied. In
general, the relative level of mRNA expression was higher in VSMCs
than osteoblasts; however, in the case of Sm22α and Acta2, bone-
forming osteoblasts expressed more mRNA than calcifying VSMCs.
Additionally, strong Sm22α and Acta2 protein expression was observed
in osteoblasts at all stages of diﬀerentiation, and in the case of Sm22α
Fig. 8. The same functional diﬀerences in bone formation and VSMC calciﬁcation are observed when cells are grown in identical tissue culture conditions. (A) Osteoblasts
cultured in 1 mM β-glycerophosphate + 1 mM sodium phosphate form large mineralised bone nodules and display widespread collagen deposition and TNAP
staining. VSMCs grown in the same conditions form small discrete regions of calciﬁcation that are not associated with TNAP staining. Col1α1 immunostaining in
VSMCs is cell associated (Scale bars: phase contrast = 250 μm, immunoﬂuorescence = 50 μm, TEM = 1 μm). The level of (B) bone formation is similar in cells
cultured under the original versus new conditions. (C) The level of VSMC calciﬁcation was increased by 40% in the new conditions. Comparison of (D) cell number,
(E) cell viability, (F) ATP release and (G) TNAP activity shows that the functional diﬀerences between osteoblasts and VSMCs are the same in cells cultured in the
original and new conditions. Original conditions: 2 mM β-glycerophosphate (osteoblasts) or 2 mM sodium orthophosphate (VSMCs). New conditions: 1 mM β-
glycerophosphate + 1 mM sodium phosphate. Values are mean ± SEM (n = 6–12 replicate wells), *** = p < 0.001, ** = p < 0.01.
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levels were higher in osteoblasts than VSMCs. These ﬁndings are con-
sistent with previous studies which reported expression of VSMC mar-
kers (e.g. Acta2, calponin, Myh10) by osteoblasts and mesenchymal
stem cells [51–56]. Thus, despite being widely used in publications,
these proteins may not represent the most appropriate markers for
studying the loss of/change in VSMC phenotype in a calcifying en-
vironment.
Controlled ATP release has been demonstrated from many cell types
including VSMCs and osteoblasts [31,57]. This study found that ex-
tracellular ATP levels were higher in cultures of calcifying VSMCs than
control VSMCs. ATP can act via P2 receptors to inhibit bone miner-
alisation [29,58] and AMC [40,59]. Furthermore, ATP can also be
broken down by NPPs to produce pyrophosphate. Thus, the increase in
ATP release from calcifying VSMCs could reﬂect a mechanism by which
the cells are attempting to prevent further calciﬁcation by releasing
local inhibitors. However, since calcifying VSMCs also display reduced
cell viability the higher extracellular ATP levels could also reﬂect the
release of intracellular ATP from dying cells.
Many of the experimental protocols employed to model AMC in vitro
do so by increasing the extracellular phosphate levels in the culture
medium. The additional phosphate added varies from 2mM to 10mM
and is usually in the form of sodium phosphate [40,60,61] or, occa-
sionally, β-glycerophosphate [10,39]. Even in severe hyperpho-
sphatemia, serum phosphate levels of over 3mM are rare in vivo; thus,
the experimental study of higher phosphate concentrations may have
little pathophysiological relevance. Furthermore, a recent investigation
by Hortells et al. [62] reported that higher concentrations of phosphate
(≥3mM) will saturate the tissue culture medium leading to non-spe-
ciﬁc, non-cell mediated calcium phosphate precipitation. The same also
applies to osteoblasts since culture with ≥5mM β-glycerophosphate
leads to reduced cell viability and widespread non-speciﬁc mineralisa-
tion that is not true bone formation (Figs. 1 and 5) [26,28]. Thus, to
avoid confounding results caused by dystrophic mineral deposition, this
study used low, physiologically relevant phosphate concentrations
(2 mM) to compare AMC and bone formation. Since β-glycerophosphate
failed to induce VSMC calciﬁcation within 14 days, sodium orthopho-
sphate was used in the VSMC experiments. Sodium orthophosphate was
not suitable for osteoblast cultures because, even at 2mM, it resulted in
non-speciﬁc mineral deposition and increased cell death. Both of these
events are not representative of the in vivo physiological situation and
therefore not appropriate to use. The comparison of cells grown in
diﬀerent conditions represents a potential limitation of the ﬁndings
presented as it is possible that the diﬀering forms of phosphate con-
tributed to some of the functional diﬀerences observed. Therefore, we
also sought to identify culture conditions which allow both regulated
bone formation and VSMC calciﬁcation. A combination approach of
1 mM β-glycerophosphate + 1 mM sodium phosphate proved to be the
most eﬀective approach. Osteoblasts and VSMCs cultured using this
medium supplementation behaved in the same way as cells grown in
the original culture conditions. Taken together, this suggests that the
functional diﬀerences observed between in vitro bone formation and
VSMC calciﬁcation are most likely cell-mediated rather than due to the
culture conditions.
In summary, this study showed that VSMCs cultured in a high
phosphate environment undergo phenotypic changes to develop some
limited osteoblast-like properties. However, calcifying mouse VSMCs
diﬀer signiﬁcantly from mature, bone-forming mouse osteoblasts and
instead appear to display a phenotype that is in between that of a
normal cultured VSMC and a mature osteoblast. It should be empha-
sised that this comparison is for in vitro studies where calciﬁcation has
been induced solely by increasing extracellular phosphate levels.
However, given the widespread use of in vitro models in vascular cal-
ciﬁcation research it is important that the diﬀerences between osteo-
blasts and calcifying VSMCs are acknowledged in order to prevent in-
accurate or over interpretation of research ﬁndings. Ultimately,
understanding the diﬀerences between VSMCs and osteoblasts may
help develop therapeutic strategies which prevent pathological AMC
without impacting physiological skeletal mineralisation.
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